Not only clinical trials but also animal experiments indicate GLP‐1R agonists could improve neurodegenerative diseases, such as Parkinson's disease13, 14 and Alzheimer's disease,15, 16 while GLP‐1R also exerts therapeutic efficacy on brain ischemia,17, 18 traumatic brain injury,19 and psychiatric disorders20, 21, 22 in animal models. This evidence concerns the gene GLP1R and early-onset autosomal dominant Alzheimer disease.